Molly Davies* , Matthew G Davey and Nicola Miller
Breast cancer is the commonest cancer among women worldwide. Despite the rising incidence of the disease, significant improvement in breast cancer patient outcomes has been observed in recent years. These improved clinical and survival outcomes coincide with our enhanced appreciation for the processes of cancer development as well as the advances in therapeutic strategy for breast cancer patient management. In recent times, the translational research paradigm has evolved to understand that microRNA (small, non-coding molecules, 19-25 nucleotides in length) are key modulators in oncogenesis. Monitoring miRNA expression patterns is perceived to be informative in predicting response to conventional breast cancer therapeutics and providing prognostication. This Mini-Review will provide a concise summary of current efforts to exploit aberrant miRNA profiles to identify novel therapeutic targets and the focus on correlating miRNA expression levels with response to current treatment strategies.
